Moreover, in a placebo-controlled phase 2 clinical trial, administration of inhaled, nebulized IFN-β (to patients already admitted to the hospital due to COVID-19 symptoms) resulted in a higher chance of disease improvement and a more rapid recovery from COVID-19 [40]. Here, IFNB1 is linked to COVID-19.